CURIS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.84 USD | +1.15% |
|
-2.22% | +24.24% |
| May. 07 | Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 07 | Transcript : Curis, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Presenter SpeechStephen Bersey (Analysts)Welcome, everyone. Thank you for joining us at the H....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Calendar
04:30pm
- Business Update Call
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.66
USD
Average target price
79.8
USD
Spread / Average Target
+409.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.24% | 92.3M | |
| +28.45% | 48.16B | |
| -1.08% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +10.12% | 25.59B | |
| -22.94% | 18.96B | |
| +8.01% | 12.92B | |
| +29.01% | 12.03B | |
| -1.90% | 11.77B |
- Stock Market
- Equities
- CRIS Stock
- News Curis, Inc.
- Transcript : Curis, Inc. Presents at H.C. Wainwright Virtual Global Life Sciences Conference, Mar-09-2021 07
